Effect Of Rosuvastatin And Fluvastatin On Bone Mineral Density In Postmenopausal Coronary Heart Disease Patients With Osteoporosis

BackgroundStatins are3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA). Which are included in the primary and secondary prevention of cardiovascular and cerebrovascular diseases drugs after being used in clinical in the1980s. Statins can change the fibrinolytic activity in patients with coronary heart disease significantly and reduce the incidence of sudden cardiac death. Several studies have also shown that Statins can promote the formation of new bone,also impact the bone resorption conspicuously, increase bone density, recovery Micro-structure, increase its strength and thus reduce the risk of fracture prevention and treatment of osteoporosis. However, not many studies of the relationship between coronary heart disease and osteoporosis clinical coronary heart disease in women, especially menopause.Calcification Are present in atherosclerotic arterie, but rarely seen in the normal arterial wall, Studies have shown that the biological characteristics of arterial calcification cells and bone are increasingly consistent and parallel. Large number of domestic and international studys show that statins have cross effect on cardiovascular disease risk factors. Recently, Cholesterol and vitamin D have a close relationship both of which go through7-dehydrocholesterol metabolic pathways, Studys in recent years found that vitamin D is an important factor that can affect the bone mineral density (BMD). Statins is recognized as the preferred drug for the treatment of high cholesterol.researchers found that HMG-CoA reductase inhibitors can increase the formation of osteoblasts. Whether coronary heart disease and osteoporosis are intrinsically linked responsing to lipid-lowering drugs. Although there are many evidences that statins can protect bone in vitro cell culture and animal studies. However, there are still a lot of controversies in clinical studies about this problem. In this study, by comparing the effective of statin drugs on blood lipids and bone mineral density and bone metabolism indicators in menopause coronary heart disease and osteoporosis, we can take reasonable preventive measures in clinical..objectiveTo investigate the effects of Rosuvastatin and Fluvastatin on serum lipids, bone mineral density (BMD) and Osteal-metabolize markers in postmenopausal coronary heart disease patients with osteoporosis.Method117postmenopausal coronary heart disease patients with osteoporosis were randomly classed into A group(n=60) and B group (n=57). Rosuvastatin10mg QN in A group,. Fluvastatin80mg QN in B group. Phase of treatment lasted for40weeks. Serum lipids and bone mineral density were measured before treatment and after40weeks. Osteal-metabolize markers were tested at the same time.Resultcompared with pretherapy, serum total cholesterol (TC), triglycerides(TG), And low density lipoprotein cholesterol (LDL) were lower, High density lipoprotein cholesterol (HDL) was higher after treatment in both groups (p<0.05), The variation of serum lipids in A group were more significant than those in B group (p<0.05). The parameter value of bone density at lumar vertebrae2～4and proximal femur (Neck and Troch) were all significantly increased in two groups (p＜0.05). The differentiation of the range was not significant. Osteal-metabolize markers were not significantly changed in two groups after treatment.ConclusionBoth Rosuvastatin and Fluvastatin have satisfactory regulations on hyperlipoidemia in postmenopausal CHD with osteoporosis and the A group has significant advantage over the B group. Both Rosuvastatin and Fluvastatin may increased bone density on postmenopausal CHD with osteoporosis.